Listeria meningitis complicating infliximab treatment for Crohn's disease

41Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Infliximab, a monoclonal antibody directed against tumour necrosis factor-alpha, is an effective therapy for Crohn's disease. Though uncommon, serious opportunistic infections, including reactivation of tuberculosis, have occurred in patients after infliximab administration. Meningitis caused by Listeria monocytogenes developed in a 37-year-old man six days after the second infusion of infliximab. The patient, who also was treated with azathioprine and corticosteroids, had an uneventful recovery after a course of antibiotics. Several other recent reports have implicated infliximab therapy in the development of severe Listeria infections, particularly meningitis and sepsis. With the increasing use of tumour necrosis factor-alpha-neutralizing agents, clinicians should be aware of the risk of opportunistic infections caused by L monocytogenes in patients with Crohn's disease following infliximab treatment. ©2005 Pulsus Group Inc. All rights reserved.

Cite

CITATION STYLE

APA

Williams, G., Khan, A. A., & Schweiger, F. (2005). Listeria meningitis complicating infliximab treatment for Crohn’s disease. Canadian Journal of Infectious Diseases and Medical Microbiology, 16(5), 289–292. https://doi.org/10.1155/2005/814698

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free